Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkisnsonism
CONCLUSIONS: In our experience, FUS VIM-thalamotomy was effective in patients with MSA-P and DLB. Larger, controlled studies are needed to verify our preliminary observations.PMID:38476865 | PMC:PMC10932618 | DOI:10.1155/2024/6643510 (Source: Parkinsons Disease)
Source: Parkinsons Disease - March 13, 2024 Category: Neurology Authors: Alon Sinai Maria Nassar Lev Shornikov Marius Constantinescu Menashe Zaaroor Ilana Schlesinger Source Type: research
Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease
Parkinsons Dis. 2024 Feb 21;2024:3885451. doi: 10.1155/2024/3885451. eCollection 2024.ABSTRACTIn Parkinson's disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinso...
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Alina Ben ítez-Castañeda Ver ónica Anaya-Martínez Armando de Jes ús Espadas-Alvarez Ana Luisa Gutierrez-V áldez Luis Fernando Razgado-Hern ández Patricia Emmanuelle Reyna-Velazquez Liz Quintero-Macias Daniel Mart ínez-Fong Benjam ín Florán-Gardu Source Type: research
Improvement by Medication Less than Expected in Parkinson's Disease: Blinded Evaluation of Levodopa Response
CONCLUSIONS: We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient's subjective evaluation.PMID:38419645 | PMC:PMC10901577 | DOI:10.1155/2024/2649578 (Source: Parkinsons Disease)
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Mette Niemann Johansen Anna Handberg Mohamed El Haddouchi Josefine Grundtvig Steen Rusborg Jensen Lisette Salvesen Annemette L økkegaard Source Type: research
Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease
Parkinsons Dis. 2024 Feb 21;2024:3885451. doi: 10.1155/2024/3885451. eCollection 2024.ABSTRACTIn Parkinson's disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinso...
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Alina Ben ítez-Castañeda Ver ónica Anaya-Martínez Armando de Jes ús Espadas-Alvarez Ana Luisa Gutierrez-V áldez Luis Fernando Razgado-Hern ández Patricia Emmanuelle Reyna-Velazquez Liz Quintero-Macias Daniel Mart ínez-Fong Benjam ín Florán-Gardu Source Type: research
Improvement by Medication Less than Expected in Parkinson's Disease: Blinded Evaluation of Levodopa Response
CONCLUSIONS: We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient's subjective evaluation.PMID:38419645 | PMC:PMC10901577 | DOI:10.1155/2024/2649578 (Source: Parkinsons Disease)
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Mette Niemann Johansen Anna Handberg Mohamed El Haddouchi Josefine Grundtvig Steen Rusborg Jensen Lisette Salvesen Annemette L økkegaard Source Type: research
Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease
Parkinsons Dis. 2024 Feb 21;2024:3885451. doi: 10.1155/2024/3885451. eCollection 2024.ABSTRACTIn Parkinson's disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinso...
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Alina Ben ítez-Castañeda Ver ónica Anaya-Martínez Armando de Jes ús Espadas-Alvarez Ana Luisa Gutierrez-V áldez Luis Fernando Razgado-Hern ández Patricia Emmanuelle Reyna-Velazquez Liz Quintero-Macias Daniel Mart ínez-Fong Benjam ín Florán-Gardu Source Type: research
Improvement by Medication Less than Expected in Parkinson's Disease: Blinded Evaluation of Levodopa Response
CONCLUSIONS: We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient's subjective evaluation.PMID:38419645 | PMC:PMC10901577 | DOI:10.1155/2024/2649578 (Source: Parkinsons Disease)
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Mette Niemann Johansen Anna Handberg Mohamed El Haddouchi Josefine Grundtvig Steen Rusborg Jensen Lisette Salvesen Annemette L økkegaard Source Type: research
Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease
Parkinsons Dis. 2024 Feb 21;2024:3885451. doi: 10.1155/2024/3885451. eCollection 2024.ABSTRACTIn Parkinson's disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinso...
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Alina Ben ítez-Castañeda Ver ónica Anaya-Martínez Armando de Jes ús Espadas-Alvarez Ana Luisa Gutierrez-V áldez Luis Fernando Razgado-Hern ández Patricia Emmanuelle Reyna-Velazquez Liz Quintero-Macias Daniel Mart ínez-Fong Benjam ín Florán-Gardu Source Type: research
Improvement by Medication Less than Expected in Parkinson's Disease: Blinded Evaluation of Levodopa Response
CONCLUSIONS: We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient's subjective evaluation.PMID:38419645 | PMC:PMC10901577 | DOI:10.1155/2024/2649578 (Source: Parkinsons Disease)
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Mette Niemann Johansen Anna Handberg Mohamed El Haddouchi Josefine Grundtvig Steen Rusborg Jensen Lisette Salvesen Annemette L økkegaard Source Type: research
Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson's Disease
Parkinsons Dis. 2024 Feb 21;2024:3885451. doi: 10.1155/2024/3885451. eCollection 2024.ABSTRACTIn Parkinson's disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinso...
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Alina Ben ítez-Castañeda Ver ónica Anaya-Martínez Armando de Jes ús Espadas-Alvarez Ana Luisa Gutierrez-V áldez Luis Fernando Razgado-Hern ández Patricia Emmanuelle Reyna-Velazquez Liz Quintero-Macias Daniel Mart ínez-Fong Benjam ín Florán-Gardu Source Type: research
Improvement by Medication Less than Expected in Parkinson's Disease: Blinded Evaluation of Levodopa Response
CONCLUSIONS: We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient's subjective evaluation.PMID:38419645 | PMC:PMC10901577 | DOI:10.1155/2024/2649578 (Source: Parkinsons Disease)
Source: Parkinsons Disease - February 29, 2024 Category: Neurology Authors: Mette Niemann Johansen Anna Handberg Mohamed El Haddouchi Josefine Grundtvig Steen Rusborg Jensen Lisette Salvesen Annemette L økkegaard Source Type: research